VYD 2311
Alternative Names: VYD-2311Latest Information Update: 11 Sep 2024
At a glance
- Originator Invivyd
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 04 Sep 2024 Phase-I clinical trials in COVID-2019 infections (In volunteers) in Australia (IM) (NCT06523153)
- 04 Sep 2024 Phase-I clinical trials in COVID-2019 infections (In volunteers) in Australia (IV) (NCT06523153)
- 03 Sep 2024 Updated pharmacodynamics data from a preclinical studies in COVID-2019 infections released by Invivyd